SCHEMBL2138729

SCHEMBL2138729

CN(C)C1(Cc2ccccc2)CCC2(CC1)c1[nH]c3ccccc3c1CCN2C(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 6/20 0.51
OGFRL1 Q5TC84 3/20 0.51
OPRL1 P41146 3/20 0.44
HTT P42858 1/20 0.38
LMNA P02545 1/20 0.37
HRH4 Q9H3N8 1/20 0.35
KMT2A Q03164 1/20 0.35
SIRT6 Q8N6T7 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ADRB2 P07550 1/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TRPA1 O75762 2/20 0.34
TRPV1 Q8NER1 1/20 0.34
HPGD P15428 1/20 0.34
PDE5A O76074 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2142957 0.85 OPRM1 (0.52) OPRM1OGFRL1OPRL1KMT2AKDM4E
SCHEMBL2141768 0.85 OPRM1 (0.49) OPRM1OGFRL1OPRL1LMNAKMT2A
SCHEMBL2139574 0.82 OPRM1 (0.54) OPRM1OGFRL1OPRL1KMT2AKDM4E
SCHEMBL2140032 0.82 OPRM1 (0.54) OPRM1OGFRL1OPRL1LMNAKMT2A
SCHEMBL10065020 0.82 OPRM1 (0.53) OPRM1OGFRL1OPRL1LMNAKMT2A
SCHEMBL2141896 0.82 OPRM1 (0.51) OPRM1OGFRL1OPRL1LMNAHRH4
SCHEMBL2140335 0.82 OPRM1 (0.58) OPRM1OGFRL1OPRL1LMNAKMT2A
SCHEMBL2141136 0.82 OPRM1 (0.54) OPRM1OGFRL1OPRL1LMNAHRH4
SCHEMBL2141647 0.82 OPRM1 (0.54) OPRM1OGFRL1OPRL1LMNAKMT2A
SCHEMBL2141092 0.80 OPRM1 (0.52) OPRM1OGFRL1OPRL1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor GRUENENTHAL GMBH (DE) 2008-09-11 US claimed
US-20160271107-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2016-09-22 US disclosed
US-20160271107-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2016-09-22 US disclosed
US-20140303125-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2014-10-09 US disclosed
US-20140303125-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2014-10-09 US disclosed
EP-1868600-B1 SPIROCYCLIC CYCLOHEXANE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE DEPENDENCY GRUENENTHAL GMBH (DE) 2012-06-27 EP disclosed
EP-1868600-B1 SPIROCYCLIC CYCLOHEXANE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE DEPENDENCY GRUENENTHAL GMBH (DE) 2012-06-27 EP disclosed
US-8034936-B2 Spirocyclic cyclohexane compounds useful to treat substance dependency GRUENENTHAL GMBH (DE) 2011-10-11 US disclosed
US-8034936-B2 Spirocyclic cyclohexane compounds useful to treat substance dependency GRUENENTHAL GMBH (DE) 2011-10-11 US disclosed
US-20110053970-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2011-03-03 US disclosed
US-20110053970-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency GRUENENTHAL GMBH (DE) 2011-03-03 US disclosed
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor GRUENENTHAL GMBH (DE) 2008-09-11 US disclosed
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor GRUENENTHAL GMBH (DE) 2008-09-11 US disclosed
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor GRUENENTHAL GMBH (DE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221141-A1 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor OPRM1, OPRK1, OPRD1 OPRM1 1/4885OGFRL1 34/4885OPRL1 4/4885
US-20110053970-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency TACR2, OPRK1, OPRD1 OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885
US-20140303125-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency TACR2, OPRK1, OPRD1 OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885
US-20160271107-A1 Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency TACR2, OPRK1, OPRD1 OPRM1 8/4885OGFRL1 307/4885OPRL1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.